SG10201400978PA - Oligonucleotide analogues incorporating 5-aza-cytosine therein - Google Patents

Oligonucleotide analogues incorporating 5-aza-cytosine therein

Info

Publication number
SG10201400978PA
SG10201400978PA SG10201400978PA SG10201400978PA SG10201400978PA SG 10201400978P A SG10201400978P A SG 10201400978PA SG 10201400978P A SG10201400978P A SG 10201400978PA SG 10201400978P A SG10201400978P A SG 10201400978PA SG 10201400978P A SG10201400978P A SG 10201400978PA
Authority
SG
Singapore
Prior art keywords
aza
cytosine
oligonucleotide analogues
analogues incorporating
incorporating
Prior art date
Application number
SG10201400978PA
Other languages
English (en)
Inventor
Pasit Phiasivongsa
Sanjeev Redkar
Original Assignee
Astex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37894870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201400978P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Pharmaceuticals Inc filed Critical Astex Pharmaceuticals Inc
Publication of SG10201400978PA publication Critical patent/SG10201400978PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201400978PA 2005-09-29 2006-09-25 Oligonucleotide analogues incorporating 5-aza-cytosine therein SG10201400978PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/241,799 US7700567B2 (en) 2005-09-29 2005-09-29 Oligonucleotide analogues incorporating 5-aza-cytosine therein

Publications (1)

Publication Number Publication Date
SG10201400978PA true SG10201400978PA (en) 2014-08-28

Family

ID=37894870

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201400978PA SG10201400978PA (en) 2005-09-29 2006-09-25 Oligonucleotide analogues incorporating 5-aza-cytosine therein
SG201007143-9A SG166112A1 (en) 2005-09-29 2006-09-25 Oligonucleotide analogues incorporating 5-aza-cytosine therein

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG201007143-9A SG166112A1 (en) 2005-09-29 2006-09-25 Oligonucleotide analogues incorporating 5-aza-cytosine therein

Country Status (22)

Country Link
US (7) US7700567B2 (ko)
EP (2) EP1943264B1 (ko)
JP (1) JP5030958B2 (ko)
KR (2) KR20130137725A (ko)
CN (1) CN101282986B (ko)
AU (1) AU2006297375C1 (ko)
CA (2) CA2623090C (ko)
CY (1) CY1116876T1 (ko)
DK (2) DK2944646T3 (ko)
ES (2) ES2782998T3 (ko)
HK (1) HK1120518A1 (ko)
HU (1) HUE025782T2 (ko)
IL (2) IL190248A (ko)
MY (1) MY145619A (ko)
NO (1) NO344764B1 (ko)
NZ (2) NZ566617A (ko)
PL (1) PL1943264T3 (ko)
PT (1) PT1943264E (ko)
SG (2) SG10201400978PA (ko)
SI (1) SI1943264T1 (ko)
WO (1) WO2007041071A2 (ko)
ZA (1) ZA200803522B (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
WO2009016617A2 (en) * 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
US8466276B2 (en) 2008-02-22 2013-06-18 Nektar Therapeutics Oligomer conjugates of heteropentacyclic nucleosides
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
BR112012000828A8 (pt) 2009-07-06 2017-10-10 Ontorii Inc Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
KR102004559B1 (ko) * 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
EP2869852A4 (en) * 2012-07-09 2016-04-20 Metheor Therapeutics Corp Oligonucleotide inhibitors of DNA methyltransferases and their use in the treatment of diseases
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP2914254B1 (en) * 2012-10-30 2020-01-08 MEI Pharma, Inc. Combination therapies to treat chemoresistant cancers
CN110448566A (zh) * 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
CN103305604B (zh) * 2013-05-09 2015-05-06 宁波大学 可用于检测与冠心病相关的cdkn2b基因启动子区甲基化程度的试剂盒及其应用
WO2014204856A1 (en) * 2013-06-17 2014-12-24 Catabasis Pharmaceuticals, Inc. Fatty acid anticancer derivatives and their uses
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
JP6768722B2 (ja) * 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
WO2017049192A1 (en) 2015-09-17 2017-03-23 University Of Massachusetts Compositions and methods for modulating fmr1 expression
JP6162349B1 (ja) * 2016-04-21 2017-07-12 大原薬品工業株式会社 ５−アザシチジン類の糖部シリルエーテル誘導体
US10227374B2 (en) * 2016-04-21 2019-03-12 Ohara Pharmaceutical Co., Ltd. Silyl etherified derivatives of 5-azacytidines in carbohydrate moiety
WO2017183215A1 (ja) * 2016-04-21 2017-10-26 大原薬品工業株式会社 ５－アザシチジン類の糖部シリルエーテル誘導体
CN110088113A (zh) * 2016-11-23 2019-08-02 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
CN106929476A (zh) * 2017-03-29 2017-07-07 大连理工大学 一种去甲基化试剂在人白血病细胞中的应用
EP3634972A2 (en) 2017-07-11 2020-04-15 Teva Czech Industries s.r.o. Improved processes for the preparation of guadecitabine and intermediates thereof
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
CA3103436A1 (en) * 2018-06-11 2019-12-19 The Regents Of The University Of California Demethylation to treat eye disease
CN109232692A (zh) * 2018-09-14 2019-01-18 中国医学科学院放射医学研究所 一种脱氧胞苷类有机合成中间体及其制备方法
CA3110224A1 (en) * 2018-09-25 2020-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
KR102280330B1 (ko) * 2018-10-19 2021-07-21 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
CN110215740B (zh) * 2019-07-15 2021-05-04 大连医科大学 一种两性离子亲水前处理硅胶材料的制备方法
CN113425293B (zh) * 2021-06-29 2022-10-21 上海交通大学医学院附属新华医院 一种听觉失认障碍评估系统及方法

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2105468A1 (en) 1970-04-23 1971-11-18 Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen 1-glycosyl-5-aza-cytosines prepn
US5157120A (en) * 1980-09-16 1992-10-20 Syntex (U.S.A.) Inc. Guanine derivatives
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
JPS61161204A (ja) * 1985-01-10 1986-07-21 レプリゲン　コーポレーシヨン 抗植物ウイルス剤
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US4740560A (en) * 1986-04-17 1988-04-26 The Dow Chemical Company ABS resins and process for making them
GB8612826D0 (en) 1986-05-27 1986-07-02 Boots Co Plc Insecticidal compositions
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
DE3712786A1 (de) 1987-04-15 1988-11-03 Merck Patent Gmbh Verfahren und mittel zur bestimmung von nucleinsaeuren
CS269077B1 (cs) 1987-10-01 1990-04-11 Piskala Alois Způsob přípravy 5-azacytosinů
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US4904770A (en) 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5324831A (en) * 1988-04-06 1994-06-28 The United States Of America As Represented By The Secretary Of Health And Human Services Phosphoramidite reagent for chemical synthesis of modified DNA
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
ES2160579T3 (es) 1991-07-05 2001-11-16 Pro Neuron Inc Tratamiento de la toxicidad de un agente quimioterapeutico y un agente antivirico con nucleosidos de pirimidina acilados.
IL103311A0 (en) 1991-10-07 1993-03-15 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
JPH05219974A (ja) 1992-02-13 1993-08-31 Mitsui Petrochem Ind Ltd トロパンアルカロイドの製造方法
JPH05246891A (ja) 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
JPH09506253A (ja) 1993-11-30 1997-06-24 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼの阻害
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
EP0871707A4 (en) 1995-05-19 2000-10-25 Phytera Inc MANIPULATION OF VEGETABLE CELL AND TISSUE CULTURES
DE69637669D1 (de) 1995-06-06 2008-10-16 Osiris Therapeutics Inc Myogene differenzierung menschlicher mesenchymaler stammzellen
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
DE69629702T2 (de) 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad Liposomale oligonukleotidzusammensetzungen
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
EP0876149A4 (en) 1995-12-22 2001-09-26 Univ East Carolina PROCESS FOR THE TREATMENT OF CHARACTERIZED DISORDERS BY OVEREXPRESSION OF CYTIDINE-DESAMINASE OR DESOXYCYTIDINE-DESAMINASE
PL187107B1 (pl) 1996-10-16 2004-05-31 Icn Pharmaceuticals L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie
US6423692B2 (en) 1997-04-24 2002-07-23 Dana-Farber Cancer Institute, Inc. Method of enhancing the effectiveness of DCK phosphorylated molecules
WO1999012027A1 (en) 1997-08-29 1999-03-11 The Regents Of The University Of California Modulators of dna cytosine-5 methyltransferase and methods for use thereof
US6153383A (en) * 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
EP1123111B1 (en) 1998-10-19 2004-09-15 Methylgene, Inc. Modulation of dna methyltransferase expression by combination therapy
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
WO2000040269A2 (en) 1999-01-05 2000-07-13 Lee Clarence C Pharmaceutical compositions for treatment of diseased tissues
AU4347500A (en) 1999-04-13 2000-11-14 Rutgers, The State University Of New Jersey Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
JP2003503313A (ja) 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
DE19935303A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
JP2001163776A (ja) 1999-09-30 2001-06-19 Nisshin Oil Mills Ltd:The 安定化された液剤
EP1224303A2 (en) 1999-10-18 2002-07-24 Emory University Tms1 compositions and methods of use
US20020115117A1 (en) 2000-03-15 2002-08-22 Shuk-Mei Ho ERbeta-mediated gene expression
JP3771218B2 (ja) 2000-09-08 2006-04-26 ソウル ナショナル ユニバーシティー インダストリー ファンデーション 細胞老化関連核酸配列及びタンパク質
US6858935B1 (en) 2000-12-07 2005-02-22 Cadence Design Systems, Inc. Simulating euclidean wiring directions using manhattan and diagonal directional wires
EP1351678A2 (en) 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2002223753A (ja) 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
EP1357930B1 (en) 2001-02-05 2005-11-02 Innoventus Project AB Histidine-rich glycoprotein (hrgp) for inhibiting angiogenesis
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US20060194275A1 (en) 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2444894C (en) 2001-04-26 2013-06-25 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
EP1402071A4 (en) 2001-06-08 2005-12-14 Us Genomics Inc METHOD AND PRODUCTS FOR THE ANALYSIS OF NUCLEIC ACIDS BASED ON THE METHYLATION STATUS
JP2002370939A (ja) 2001-06-12 2002-12-24 Taisho Pharmaceut Co Ltd 育毛剤
AU2002312487A1 (en) * 2001-06-15 2003-01-02 Ribapharm Nucleoside vaccine adjuvants
SE518759C2 (sv) 2001-07-27 2002-11-19 Geneinvent Bbl Ab Vektorer motståndskraftiga mot metylering
US20030045497A1 (en) 2001-07-27 2003-03-06 Geneinvent Bbl Ab Methylation resistant vectors
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
DE60234708D1 (de) 2001-09-05 2010-01-21 Chemgenex Pharmaceuticals Ltd Behandlung von sti571-resistenter oder -intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen
IN2014DN10834A (ko) 2001-09-17 2015-09-04 Psivida Inc
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
WO2003026574A2 (en) 2001-09-24 2003-04-03 Au Jessie L-S Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
US7432050B2 (en) 2001-10-05 2008-10-07 Case Western Reserve University Methods and compositions for detecting colon cancers
KR100616369B1 (ko) 2001-11-08 2006-08-28 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 벼의 트랜스포존 유전자
CN1615131A (zh) 2001-11-23 2005-05-11 中外制药株式会社 肿瘤靶向酶的鉴定方法
ATE446106T1 (de) 2001-11-29 2009-11-15 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
US20050080027A1 (en) 2001-11-30 2005-04-14 Markus Horer Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
GB0201498D0 (en) 2002-01-23 2002-03-13 Biotech Res Ventures Pte Ltd Materials and methods for treating cancer
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
CA2373890C (en) * 2002-02-28 2006-11-28 Portes Patio Resiver Inc Stress distribution hole for window sash
WO2003076660A1 (en) 2002-03-13 2003-09-18 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
JP2003310293A (ja) 2002-04-26 2003-11-05 Mitsui Chemicals Inc ヌクレオシド化合物の製造法
LT1507556T (lt) 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
CA2488382A1 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
EP1748792B1 (en) 2004-05-26 2009-02-11 Biovaxim Limited Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CA2586844A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
WO2006071983A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070105792A1 (en) 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
US20070117776A1 (en) 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
CN101361718B (zh) 2008-09-26 2013-08-28 深圳万乐药业有限公司 稳定的地西他滨冻干制剂的制备方法
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
JP6121904B2 (ja) 2010-09-08 2017-04-26 ハロザイム インコーポレイテッド 条件的活性治療用タンパク質を評価および同定する、または発展させる方法
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
WO2013117969A1 (en) 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN110448566A (zh) 2013-03-01 2019-11-15 阿斯泰克斯制药公司 药物组合
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物

Also Published As

Publication number Publication date
CN101282986A (zh) 2008-10-08
KR101478369B1 (ko) 2015-01-02
US8461123B2 (en) 2013-06-11
WO2007041071A2 (en) 2007-04-12
AU2006297375C1 (en) 2016-06-16
DK1943264T3 (en) 2015-10-26
EP1943264B1 (en) 2015-07-29
KR20130137725A (ko) 2013-12-17
JP2009509531A (ja) 2009-03-12
AU2006297375B2 (en) 2012-06-07
CA2623090A1 (en) 2007-04-12
NO20082050L (no) 2008-06-27
CA2895866C (en) 2018-09-04
EP2944646B1 (en) 2020-01-08
IL190248A0 (en) 2008-11-03
EP1943264A4 (en) 2013-08-14
US20130236536A1 (en) 2013-09-12
US20160130296A1 (en) 2016-05-12
US7700567B2 (en) 2010-04-20
SI1943264T1 (sl) 2016-01-29
US20200215092A1 (en) 2020-07-09
US9480698B2 (en) 2016-11-01
US10933079B2 (en) 2021-03-02
US9358248B2 (en) 2016-06-07
ES2550256T3 (es) 2015-11-05
US20100215729A1 (en) 2010-08-26
NO344764B1 (no) 2020-04-20
IL218618A (en) 2013-12-31
MY145619A (en) 2012-03-15
EP2944646A1 (en) 2015-11-18
NZ566617A (en) 2012-02-24
CA2895866A1 (en) 2007-04-12
CN101282986B (zh) 2012-06-27
ZA200803522B (en) 2009-07-29
KR20080059612A (ko) 2008-06-30
AU2006297375A1 (en) 2007-04-12
SG166112A1 (en) 2010-11-29
PT1943264E (pt) 2015-11-02
NZ597432A (en) 2013-05-31
CY1116876T1 (el) 2017-04-05
PL1943264T3 (pl) 2015-12-31
EP1943264A2 (en) 2008-07-16
ES2782998T3 (es) 2020-09-16
CA2623090C (en) 2015-11-10
US20070072796A1 (en) 2007-03-29
IL190248A (en) 2012-08-30
JP5030958B2 (ja) 2012-09-19
HK1120518A1 (en) 2009-04-03
WO2007041071A3 (en) 2007-09-20
US20170035794A1 (en) 2017-02-09
US20220000900A1 (en) 2022-01-06
US10456415B2 (en) 2019-10-29
HUE025782T2 (en) 2016-05-30
DK2944646T3 (da) 2020-04-06
IL218618A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
ZA200803522B (en) Oligonucleotide analogues incorporating 5-aza-cytosine therein
HRP20190084T1 (hr) Injektibilne paraziticidne formulacije s produljenim djelovanjem
HK1210212A1 (en) Immunostimmulatory oligoribonucleotides
HK1174122A1 (zh) 可靠的軟件更新
PL2175273T3 (pl) Środek nadający kokumi
EP1841430A4 (en) SUBSTITUTED PYRIDAZINYL AND PYRIMIDINYL-CHINOLIN-4-YLAMINE ANALOGUE
EP1950309A4 (en) ALBUMIN DENATURING AGENCY
PT1907574E (pt) Oligonucleótidos
EP1852499A4 (en) AGENT PROMOTING NEUROTISATION
GB0519245D0 (en) Purine compounds
EP1927347A4 (en) MEANS TO REDUCE BITTERNESS
EP1889660A4 (en) OZONE-GROWING AGENT
EP1824490A4 (en) PIPERAZINYL-PYRIDINE ANALOGS
GB0523811D0 (en) Mass stectrometer
GB0503509D0 (en) An improved delivery agent
ZA200804303B (en) Immunostimulatory oligoribonucleotides
HK1113463A1 (en) Immunopotentiating agent
EP1865313A4 (en) OPTICAL ISOMER SEPARATION AGENT
GB0613762D0 (en) Slabline structure
GB0507255D0 (en) Low k8
GB0500504D0 (en) Fluorescent nucleotide analogues
GB0507201D0 (en) New antiviral indolilydene analogues
ZAA200500720S (en) Retaining elements
GB0522257D0 (en) H-rtm-roha(c)
GB0509200D0 (en) Novel phosponate nucleosides